The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Final analysis of dose density with zoledronic acid treatment in metastatic breast cancer patients: ZARAS study.
J. De la Haba
No relevant relationships to disclose
A. Rodriguez-Lescure
No relevant relationships to disclose
J. M. Baena
No relevant relationships to disclose
J. Martin Liberal
No relevant relationships to disclose
S. Morales
No relevant relationships to disclose
J. I. Chacon
No relevant relationships to disclose
J. M. Lopez-Vega
No relevant relationships to disclose
I. Fernandez
No relevant relationships to disclose
D. Aguiar
No relevant relationships to disclose
A. Garcia-Palomo
No relevant relationships to disclose
R. M. Llorente
No relevant relationships to disclose
J. L. Barea
No relevant relationships to disclose
E. Alvarez
No relevant relationships to disclose
I. Blancas
No relevant relationships to disclose
Y. Fernandez
No relevant relationships to disclose
P. Sanchez Rovira
No relevant relationships to disclose
G. Vinyes
No relevant relationships to disclose